Vaxil Bio

Vaxil Bio Equity

The The Equity of Vaxil Bio (VXL.V) as of Oct 20, 2026 is 1.37 M CAD. In the previous year, The Equity was 716,000.00 CAD — a change of 90.64% (higher).

Equity

1.37 MCAD

YoY

90.64%

Last updated:

In 2025, Vaxil Bio's equity was 1.37 M CAD, a 90.64% increase from the 716,000.00 CAD equity in the previous year.

The Vaxil Bio Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
435,000.00 CAD
Jan 1, 2019
-583,000.00 CAD
Jan 1, 2020
804,000.00 CAD
Jan 1, 2021
1.70 M CAD
Jan 1, 2022
1.14 M CAD
Jan 1, 2023
891,000.00 CAD
Jan 1, 2024
716,000.00 CAD
Jan 1, 2025
1.37 M CAD
The Vaxil Bio Equity history
YEAREquityYoY
1.37 MCAD+90.64%
716,000.00CAD-19.64%
891,000.00CAD-21.57%
1.14 MCAD-33.18%
1.70 MCAD+111.44%
804,000.00CAD-237.91%
-583,000.00CAD-234.02%
435,000.00CAD-189.32%
-487,000.00CAD-174.24%
656,000.00CAD-402.30%
-217,000.00CAD-729.37%
34,479.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vaxil Bio Stock analysis

What does Vaxil Bio do? Vaxil Bio Ltd is a biotechnology company based in Toronto, Canada, specializing in immunotherapy for cancer and infectious diseases. Listed on March 2, 2011, the firm develops novel treatments using a platform based on signal peptides. Its advanced product, ImMucin, is a vaccine derived from MUC1 signal peptides that completed Phase I/II trials for multiple myeloma. The company also holds candidates for COVID-19 and tuberculosis vaccines, as well as monoclonal antibodies for oncology and infectious diseases. Additionally, Vaxil Bio has initiated a pre-clinical program for a drug delivery polymer targeting E-selectin, licensed from BGN Technologies, aiming to create targeted therapies against critical disease targets. Vaxil Bio is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Vaxil Bio's Equity

Vaxil Bio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Vaxil Bio's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Vaxil Bio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Vaxil Bio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Vaxil Bio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Vaxil Bio stock

The Equity of Vaxil Bio is 1.37 M CAD in 2025.

The Equity of Vaxil Bio changed from 716,000.00 CAD to 1.37 M CAD, representing a 90.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Vaxil Bio since 2006 – with annual values, charts, and detailed analysis.

The Equity's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Vaxil Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Vaxil Bio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Vaxil Bio